NCT05987696 2026-02-11
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
Clinical Trials
13 trialsNCT07301138 2025-12-24
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital
Phase 2 Not yet recruiting
NCT07059975 2025-11-04
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
Baylor College of Medicine
Phase EARLY_PHASE1 Recruiting
NCT07131059 2025-08-20
MRD-positive AML Clinical Study
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT05959720 2025-05-07
BRALLA
Instituto do Cancer do Estado de São Paulo
Recruiting
NCT00198991 2022-08-18
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Goethe University
Phase 4 Completed
NCT05362942 2022-05-05
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia
Beijing 302 Hospital
Phase 2 Unknown
NCT01158885 2021-10-26
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2 Terminated
NCT02724163 2021-10-08
Myechild01
University of Birmingham
Phase 3 Recruiting
NCT03760445 2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2 Withdrawn
NCT00526175 2016-01-20
LAL-BR/2001: Study Treatment to Low Risk ALL
PETHEMA Foundation
Phase 4 Completed
NCT00795756 2014-10-22
Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia
Northern Italy Leukemia Group
Phase 2/3 Completed
NCT00199004 2010-08-23
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
Johann Wolfgang Goethe University Hospital
Phase 4 Completed